FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia ...Middle East

The FDA has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera) for adults with schizophrenia. FDA Approvals

Hence then, the article about fda approves first twice yearly antipsychotic for schizophrenia was published today ( Wednesday 01/09/2021 - 07:15 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia )

Also on site :

• Anycubic Opens Deposits for Kobra X, Following Formnext Debut of Its Next-Generation Entry-Level Multicolor FDM Printer
• Numbrix 9 - December 26
• Southern Water accused of ‘failure’ after burst pipe leaves homes without running water on Christmas Day